Stille Q3 2023: Initial take on the report – positive - Redeye

Redeye see's an uplifting Q3 2023 report from Stille, which came in above our estimates both in terms of sales and EBIT, we note a particularly strong growth in the surgical instruments unit (+27% y/y). Considering that Q4 historically proves to be a robust quarter for Stille, we find the outlook for the share to be promising and believe it will trade up on today's report.

Länk till analysen i sin helhet: https://www.redeye.se/research/950419/stille-q3-2023-initial-take-on-the-report-positive?utm_source=finwire&utm_medium=RSS